Convalescent plasma and hyperimmune globulin therapy in COVID-19

References

• Nitulescu GM, Paunescu H, Moschos SA, et al. Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: mechanistic insights into current COVID‑19 therapies. Int J Mol Med. 2020;46:467–488.
   PubMed Web of Science ®Google Scholar
• Piroth L, Cottenet J, Mariet AS, et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2021;9:251-259.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). bmj 2020;371:m3939.
   PubMedGoogle Scholar
• Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. Jama. 2020;324:460–470.
   PubMed Web of Science ®Google Scholar
• Liu ST, Lin H-M, Baine I, et al. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020 Nov;26(11):1708-1713.
   Google Scholar
• Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;384:619-629.
   PubMed Web of Science ®Google Scholar
• Salazar E, Christensen PA, Graviss EA, et al. Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am J Pathol. 2020;190:2290–2303.
   PubMed Web of Science ®Google Scholar
• Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe covid-19 in older adults. N Engl J Med. 2021;384:610–618.
   PubMed Web of Science ®Google Scholar
• Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Nat Acad Sci. 2020;117:9490–9496.
   PubMed Web of Science ®Google Scholar
• Valk SJ, Piechotta V, Chai KL, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a rapid review. Cochrane Database Syst Rev. 2020;5.
   Web of Science ®Google Scholar
• Convalescent Plasma SV, Challenging A. Tool to treat COVID-19 patients—A lesson from the past and new perspectives. Biol Med Res Int. 2020;5:CD013600.
   Google Scholar
• Heidelberger M, Pedersen KO. The molecular weight of antibodies. J Exp Med. 1937;65:393–414.
   PubMedGoogle Scholar
• Von Pirquet C. Allergy. Arch Internal Med. 1911;7:383–436.
   Google Scholar
• Cohn EJ Protein product and process. Google Patents; 1945.
   Google Scholar
• Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med. ;306:1254–1258.
   PubMed Web of Science ®Google Scholar
• Duhem C, Dicato M, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol. 1994;97:79.
   PubMed Web of Science ®Google Scholar
• Restivo JS, Karafin MS Human Immunoglobulin Preparations. Transfusion Medicine and Hemostasis: Elsevier; 2019. p. 235–246.
   Google Scholar
• Zhang J, Xie B, Hashimoto K. Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav Immun. 2020;87:59–73.
   Web of Science ®Google Scholar
• Hung IFN, To KKW, Lee CK, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013 ;144:464–473.
   PubMed Web of Science ®Google Scholar
• Wolberg AS, Aleman MM, Leiderman K, et al. Procoagulant activity in hemostasis and thrombosis: virchow’s triad revisited. Anesthesia Analg. 2012;114:275–285.
   PubMed Web of Science ®Google Scholar
• Wolberg AS, Aleman MM. Influence of cellular and plasma procoagulant activity on the fibrin network. Thromb Res. 2010;125:S35–7.
   PubMed Web of Science ®Google Scholar
• Nurtop E, Villarroel PMS, Pastorino B, et al. Combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studies. Virol J. 2018;15:1–6.
   PubMed Web of Science ®Google Scholar
• Yeh KM, Chiueh TS, Siu LK, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005 ;56:919–922.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44–46.
   PubMed Web of Science ®Google Scholar
• Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10:676–678.
   PubMed Web of Science ®Google Scholar
• Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80–90.
   PubMed Web of Science ®Google Scholar
• Mora-Rillo M, Arsuaga M, Ramírez-Olivencia G, et al. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respir Med. 2015;3:554–562.
   PubMed Web of Science ®Google Scholar
• Chun S, Chung CR, Ha YE, et al. Possible transfusion-related acute lung injury following convalescent plasma transfusion in a patient with middle east respiratory syndrome. Ann Lab Med. 2016 ;36:393–395.
   PubMed Web of Science ®Google Scholar
• Okazaki H. [Transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO)]. Rinsho Byori Jap J Clin Pathol. 2013;61:399–406.
   PubMedGoogle Scholar
• Takada A, Feldmann H, Ksiazek TG, et al. Antibody-dependent enhancement of Ebola virus infection. J Virol. 2003;77:7539–7544.
   PubMed Web of Science ®Google Scholar
• Kliks SC, Nisalak A, Brandt WE, et al. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg. 1989 ;40:444–451.
   PubMed Web of Science ®Google Scholar
• Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol. 2003;13:387–398.
   PubMed Web of Science ®Google Scholar
• Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and associationwith severity of disease. Nat Commun. 2020;11:4704. doi: 10.1038/s41467-020-18450-4.
   Google Scholar
• Arvin AM, Fink K, Schmid MA, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature. 2020;584:353–363.
   PubMed Web of Science ®Google Scholar
• Krause I, Wu R, Sherer Y, et al. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations–a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfusion Med (Oxford, England). 2002;12:133–139.
   PubMed Web of Science ®Google Scholar
• Burbelo PD, Riedo FX, Morishima C, et al. Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019. J Infect Dis. 2020;222:206-213.
   Google Scholar
• Díez JM, Romero C, Gajardo R. Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens. Immunotherapy 2020;12:571–576.
   Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–273.
   PubMed Web of Science ®Google Scholar
• Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1–13.
   PubMed Web of Science ®Google Scholar
• Chauhan AJ, Wiffen LJ, Brown TPCOVID. 19: a collision of complement, coagulation and inflammatory pathways. J Thromb Haemost. 2020;18:2110–2117.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhao G, Song N, et al. Blockade of the C5a–C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018;7:1–12.
   Google Scholar
• Yu J, Yuan X, Chen H, et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood. 2020;136:2080–2089.
   Google Scholar
• Bastard P, Rosen LB, Zhang Q, et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585..
   Google Scholar
• Abolghasemi H, Eshghi P, Cheraghali AM, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study. Transfus Apher Sci. 2020;15:102875.
   Google Scholar
• Olivares-Gazca JC, Priesca-Marín JM, Ojeda-Laguna M, et al.Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: a pilot study. Rev Invest Clin. 2020;72:159–164.
   Google Scholar
• Perotti C, Baldanti F, Bruno R, et al.Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica. 2020;105:2834-2840.
   Google Scholar
• Joyner MJ, Bruno KA, Klassen SA, et al.Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clinic Proceedings. 2020;95:1888-1897.
   Google Scholar
• Shenoy AG, Hettinger AZ, Fernandez SJ, et al.Early mortality benefit with COVID-19 convalescent plasma: a matched control study. Br J Haematol. 2021;192:706–713.
   Google Scholar
• Quinti I, Lougaris V, Milito C, et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. J Allergy Clin Immunol. 2020;146:211–213.
   Google Scholar
• Soresina A, Moratto D, Chiarini M, et al.Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol. 2020;31:565–569.
   Google Scholar
• Jin H, Reed JC, Liu STH, et al.Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. J Allergy Clin Immunol Pract. 2020;8:3594–3596.
   Google Scholar
• Zhou G, Zhao Q.Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2. Int J Biol Sci. 2020;16:1718–1723.
   Google Scholar